Latest News

Phase 3 data show pembrolizumab beats chemotherapy, offering durable first-line control with fewer severe toxicities and chemo-free potential.

From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.

In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, discusses NCCN breast cancer guideline updates involving ESR1 mutation testing, targeted therapies, and pharmacists’ roles in monitoring, patient counseling, and treatment access.

Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.

Specialty pharmacy liaisons improve breast cancer care by easing access barriers, managing side effects, boosting adherence, and navigating new therapies and policies.

Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.

Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026

A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.

Pharmacists can support effective cancer pain treatment by starting constipation prevention with opioid therapy and reassessing bowel function before symptoms become a barrier to care.

Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.

Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.

The FDA expanded approval of talazoparib plus enzalutamide to HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer following a significant radiographic PFS benefit in TALAPRO-3.

Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.

Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.

A current pharmacy resident provides insights on how pharmacy students can manage the transition from student to resident.

Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.

CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly co-pay, PA workflow, and strict eligibility through 2027.

Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.

Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.

In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.

Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.